Presentation and Status in Health Basket
| Presentation | Basket | Yarpa | Pharmasoft |
|---|---|---|---|
|
Solution for Infusion 2 ml x 20 mg/ml |
|
87955 | 9290 |
|
Solution for Infusion 5 ml x 20 mg/ml |
|
87956 | 9291 |
|
Solution for Infusion 25 ml x 20 mg/ml |
|
55600 | 9781 |
Indications
Treatment of patients with metastatic colorectal cancer in combination with 5-fluorouracil and folinic acid in patients without prior chemotherapy for metastatic disease; as a single agent in patients who have failed an established 5-fluorouracil containing treatment regimen. Treatment of patients with small cell lung cancer. Treatment of patients with gastric cancer.
Contra-Indications
Chronic inflammatory bowel disease and/or bowel obstruction. Hypersensitivity to irinotecan or any of the excipients. Pregnancy and lactation. Bilirubin >3 times the upper limit of the normal range, severe bone marrow failure, WHO performance status >2, concomitant use with St. John? Wort.
Special Precautions
Should only be administered under the supervision of a physician qualified in the use of anticancer chemotherapy.
See prescribing information for full details.
Side Effects
See prescribing information for full details.
Drug interactions
Neuromuscular blocking agents. CYP3A-inducing anticonvulsant drugs (e.g., rifampicin, carbamazepine, phenobarbital or phenytoin). Consideration should be given to starting or substituting non-enzyme-inducing anticonvulsants at least one week prior to initiation of irinotecan therapy (e.g., ketoconazole) in patients requiring anticonvulsant treatment.
